Annual report pursuant to Section 13 and 15(d)

Note 10 - Income Taxes

Note 10 - Income Taxes

12 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Income Tax Disclosure [Text Block]

Note 10.

Income Taxes:

The provisions for income taxes consist of the following (in thousands):

	Year Ended June 30,
	2015			2014			2013
Earnings before income taxes consist of:
Domestic	$	121,765		$	127,681		$	127,491
Foreign		32,397			33,711			33,171
	$	154,162		$	161,392		$	160,662
Taxes on income consist of:
Currently payable:
Federal	$	28,220		$	40,967		$	37,666
State		6,165			1,709			2,012
Foreign		10,704			10,668			10,758
Net deferred:
Federal		4,401			(1,137	)		(595	)
State		292			(41	)		(7	)
Foreign		(3,355	)		(1,722	)		(1,733	)
	$	46,427		$	50,444		$	48,101

The following is a reconciliation of the federal tax calculated at the statutory rate of 35% to the actual income taxes provided (in thousands):

	Year Ended June 30,
	2015			2014			2013

Computed expected federal income tax expense	$	53,957		$	56,487		$	56,232
State income taxes, net of federal benefit		4,762			1,048			1,300
Qualified production activity deduction		(3,140	)		(3,823	)		(3,774	)
Non-taxable gain on investment		(2,905	)		0			0
Research and development tax credit		(912	)		(476	)		(1,392	)
Tax-exempt interest		0			(654	)		(568	)
Foreign tax rate differences		(4,059	)		(2,857	)		(2,587	)
Other		(1,276	)		719			(1,110	)
	$	46,427		$	50,444		$	48,101

In the year ended June 30, 2015, as a result of the recent acquisitions, the rate reflects an increase for state tax expense as well as a resulting provision to return true up from fiscal 2014. This increase is offset by the non-taxable gain which was a result of purchasing the remaining interest in CyVek. In addition the Company‘s R&D Europe subsidiary declared and paid a dividend of £46.6 million which resulted in a tax benefit of approximately $1.7 million.

Temporary differences comprising deferred taxes on the Consolidated Balance Sheets are as follows (in thousands):

	June 30
	2015			2014

Inventory	$	8,753		$	9,932
Net operating loss carryovers		34,767			0
Tax credit carryovers		3,872			0
Excess tax basis in equity investments		4,496			4,344
Deferred compensation		3,747			3,295
Other		4,712			3,088
Valuation allowance		(2,558	)		(1,806	)
Net deferred tax assets		57,789			18,853

Net unrealized gain on available-for-sale investments		(8,446	)		(2,745	)
Goodwill and intangible asset amortization		(96,401	)		(37,641	)
Depreciation		(2,394	)		(2,166	)
Other		(466	)		(516	)
Deferred tax liabilities		(107,707	)		(43,068	)
Net deferred tax liabilities	$	(49,918	)	$	(24,215	)

A deferred tax valuation allowance is required when it is more likely than not that all or a portion of deferred tax assets will not be realized. At June 30, 2015, a valuation allowance for potential capital loss carryovers on equity investments was zero as a result of improved performance of available-for-sale investments. Approximately $2.4 million of the valuation allowance at June 30, 2015 is for certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company acquired Novus, ProteinSimple, and CyVek. The remainder of the valuation allowance is for certain state tax credit carryovers generated in fiscal 2015. The Company believes it is more likely than not that these tax carryovers will not be realized. At June 30, 2014, the Company had provided a valuation allowance for potential capital loss carryovers resulting from excess tax basis in certain of its equity investments. The Company believes that it is more likely than not that the results of future operations will generate sufficient taxable income to realize the remaining deferred tax assets.

At June 30, 2015, the Company has federal and state net operating loss carryforwards of approximately $86.3 million and $77.8 million, respectively, from its fiscal 2015 acquisitions of ProteinSimple and CyVek, which are not limited under IRC Section 382. At June 30, 2015, the company has foreign net operating loss carryforwards of $2.5 million from its fiscal 2015 acquisition of Novus. The net operating loss carryforwards expire between fiscal 2016 and 2034. The Company has a deferred tax asset of $32.6 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. At June 30, 2015, the Company has federal and state tax credit carryforwards of $2.5 million and $1.3 million, respectively. The federal tax credit carryforwards expire between 2018 and 2035. The state credit carryforwards have no expiry date. The Company has a deferred tax asset of $3.5 million, net of the valuation allowance discussed above, related to the tax credit carryovers.

The Company has not recognized a deferred tax liability for unremitted earnings of approximately $43.0 million from its foreign operations because its subsidiaries have invested or will invest the undistributed earnings indefinitely, or the earnings will be remitted in a tax-neutral transaction.

The Company’s unrecognized tax benefits at June 30, 2015, 2014 and 2013, including accrued interest and penalties, were not material. The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next twelve months. The Company files income tax returns in the U.S federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company’s federal returns are subject to tax assessment for 2012 and subsequent years. State and foreign income tax returns are generally subject to examination for a period of three to five years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to one year after formal notification to the states.